Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IkBα-independent manner

Molecular Cancer Therapeutics

Volumn 4, Issue 7, 2005, Pages 1114-1120

  Tatetsu, Hiro ^a   Okuno, Yutaka ^a   Nakamura, Miki ^a   Matsuno, Fumihiko ^a   Sonoki, Takashi ^a   Taniguchi, Izumi ^a   Uneda, Shima ^a   Umezawa, Kazuo ^b   Mitsuya, Hiroaki ^a   Hata, Hiroyuki ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN D1; DEHYDROXYMETHYLEPOXYQUINOMICIN; GLIOTOXIN; I KAPPA B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL ISOLATION; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; CYTOTOXICITY; DOWN REGULATION; DRUG INHIBITION; ENZYME ACTIVATION; FEMALE; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; TRANSLOCATION LINE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CASPASE 3; CASPASES; CYCLIN D1; CYCLOHEXANONES; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; FEMALE; HUMANS; I-KAPPA B PROTEINS; MICE; MICE, INBRED ICR; MICE, SCID; MULTIPLE MYELOMA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 23144462040     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0198     Document Type: Article

References (38)

1. Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194:164-76.
2. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277:16639-47.
3. Ni H, Ergin M, Huang Q, et al. Analysis of expression of nuclear factor κB (NF-κB) in multiple myeloma: down-regulation of NF-κB induces apoptosis. Br J Haematol 2001; 115:279-86.
4. + cells derived from multiple myeloma patients, and their suppression leads to apoptosis. Blood 2003; 103:3175-84.
5. Gilmore TD. The Rel/NF-κB signal transduction pathway: introduction. Oncogene 1999;18:6842-4.
6. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-κB in the biology and treatment of multiple myeloma. Semin Oncol 2001;28: 626-33.
7. Landowski TH, Olashaw NE, Agrawal D, Dalton WS. Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells. Oncogene 2003;22:2417-21.
8. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
9. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood 1996;87:1104-12.
10. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001;20: 4519-27.
11. Mitsiades N, Mitsiades CS, Poulaki V, et al. Biologic sequelae of nuclear factor-κB blockade in multiple myeloma: therapeutic applications. Blood 2002;99:4079-86.
12. Bharti AC, Donato N, Singh S, Aggarwal BB. Curcumin (diferuloyl-methane) down-regulates the constitutive activation of nuclear factor-κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 2003; 101:1053-62.
13. Magnani M, Crinelli R, Bianchi M, Antonelli A. The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kB (NF-kB). Curr Drug Targets 2000;1: 387-99.
14. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071-6.
15. Richardson PG, Barlogie B, Berenson J, at al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-17.
16. Emmerich F, Meiser M, Hummel M, et al. Overexpression of IκBα without inhibition of NF-κB activity and mutations in the IκBα gene in Reed-Sternberg cells. Blood 1999;94:3129-34.
17. Emmerich F, Theurich S, Hummel M, et al. Inactivating IκBε mutations in Hodgkin/Reed-Sternberg cells. J Pathol 2003;201:413-20.
18. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene 1999;18:3063-70.
19. Parker KM, Ma MH, Manyak S, et al. Identification of polymorphisms of the IκBα gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet 2002;137:43-8.
20. NF-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004;103(8):3175-84. Epub 2003 Dec 18.
21. Matsumoto N, Iinuma H, Sawa T, et al. Epoxyquinomicins A, B, C and D, new antibiotics from Amycolatopsis. II. Effect on type II collagen-induced arthritis in mice. J Antibiot (Tokyo) 1997;50:906-11.
22. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J Biol Chem 2002;277: 24625-30.
23. Matsumoto N, Ariga A, To-e S, et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett 2000; 10:865-9.
24. Kikuchi E, Horiguchi Y, Nakashima J, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 2003;63:107-10.
25. Tarte K, Jourdan M, Veyrune JL, et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent anti-apoptotic factor for myeloma cells. Br J Haematol 2004;125: 373-82.
26. Nilsson K, Bennich H, Johansson SG, Ponten J. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 1970;7:477-89.
27. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M, Namba M. Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 1989;73: 199-204.
28. Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1α is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003; 120:53-5.
29. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 1995;184:39-51.
30. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
31. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFκB, STAT and AP1 transcription factor families. Histol Histopathol 2001;16:595-601.
32. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003;278:30339-47.
33. Flynn V Jr, Ramanitharan A, Moparty K, et al. Adenovirus-mediated inhibition of NF-κB confers chemo-sensitization and apoptosis in prostate cancer cells. Int J Oncol 2003;23:317-23.
34. D'Sa-Eipper C, Subramanian T, Chinnadurai G. bfl-1, a bcl-2 homologue, suppresses p53-induced apoptosis and exhibits potent cooperative transforming activity. Cancer Res 1996;56:3879-82.
35. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng G. NF-κB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci U S A 1999;96:9136-41.
36. Zong WX, Edelstein LC, Chen C, Bash J, Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 1999; 13:382-7.
37. Yata K, Sadahira Y, Otsuki T, et al. Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1. Br J Haematol 2001;114:591-9.
38. Gabrea A, Bergsagel PL, Chesi M, Shou Y, Kuehl WM. Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell 1999;3:119-23.